Meeting
2024 ASCO Genitourinary Cancers Symposium
Regulatory approvals for genitourinary (GU) cancer by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) over 20 years (2003-2023).
Authors
Sanjay Khanna
Imperial NHS Trust, London, United Kingdom
Sanjay Khanna , Naveed Sarwar , Reece Caldwell , Jonathon Krell , David Joseph Benjamin , Matthew James Hadfield , Ali Raza Khaki , Jeremy Lyle Warner , Mark Lythgoe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 432)
DOI
10.1200/JCO.2024.42.4_suppl.432
Abstract #
432
Poster Bd #
H14
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Distribution of immune-related adverse events (irAEs) across genitourinary (GU) malignancies.
First Author: Nataliya Mar
Poster
2018 Genitourinary Cancers Symposium
Immune-related adverse events (irAE) in GU cancer patients receiving immune checkpoint inhibitors.
First Author: Peter Zang
First Author: Jeddeo Paul
Poster
2021 Gastrointestinal Cancers Symposium
Response to PD-1 and PD-L1 based immunotherapy in MSS advanced colorectal cancer is impacted by metastatic disease sites.
First Author: Marwan Fakih